Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Canada: These 55 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Canada: These 55 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can AXUMIN (fluciclovine f-18) generic drug versions launch in Canada?

Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Canada Patent 2,629,227
Patent Title: COMPOSE PRECURSEUR DE COMPOSE ORGANIQUE MARQUE A L'HALOGENE RADIOACTIF (PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN LABELED ORGANIC COMPOUND)

AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug. There has been litigation on patents covering AXUMIN

The generic ingredient in AXUMIN is fluciclovine f-18. Additional details are available on the fluciclovine f-18 profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Canada?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Canada Patent 2,696,824

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can LETAIRIS (ambrisentan) generic drug versions launch in Canada?

Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Canada Patent 2,669,536
Patent Title: COMPOSITION DE TRAITEMENT DE L'HYPERTENSION PULMONAIRE (COMPOSITION FOR TREATING A PULMONARY HYPERTENSION)

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. Additional details are available on the ambrisentan profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in Canada?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Canada Patent 2,634,073
Patent Title: COMPOSITIONS THERAPEUTIQUES (THERAPEUTIC COMPOSITIONS COMPRISING INGENOL-3-ANGELATE)

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in Canada?

Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2026
Generic Entry Controlled by: Canada Patent 2,892,739
Patent Title: UTILISATION DE COMPOSES A BASE DE TETRACYCLINE SUBSTITUEE DANS LE TRAITEMENT D'AFFECTIONS CUTANEES INFLAMMATOIRES (SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS)

SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.

See drug price trends for SEYSARA.

The generic ingredient in SEYSARA is sarecycline hydrochloride. Additional details are available on the sarecycline hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Canada?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Canada Patent 2,634,923

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can AURYXIA (ferric citrate) generic drug versions launch in Canada?

Generic name: ferric citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 26, 2027
Generic Entry Controlled by: Canada Patent 2,640,763
Patent Title: METHODE PERMETTANT D'INVERSER, DE PREVENIR, DE RETARDER OU DE STABILISER LA CALCIFICATION DES TISSUS MOUS (METHOD OF REVERSING, PREVENTING, DELAYING OR STABILIZING SOFT TISSUE CALCIFICATION)

Drug Price Trends for AURYXIA
AURYXIA is a drug marketed by Keryx Biopharms. There are three patents protecting this drug. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. Additional details are available on the ferric citrate profile page.

When can AURYXIA (ferric citrate) generic drug versions launch in Canada?

Generic name: ferric citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 26, 2027
Generic Entry Controlled by: Canada Patent 2,640,974
Patent Title: METHODE DE TRAITEMENT DE NEPHROPATHIE CHRONIQUE (METHOD OF TREATING CHRONIC KIDNEY DISEASE)

Drug Price Trends for AURYXIA
AURYXIA is a drug marketed by Keryx Biopharms. There are three patents protecting this drug. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. Additional details are available on the ferric citrate profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in Canada?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Canada Patent 2,677,185
Patent Title: METHODE DE PREPARATION DE PARTICULES COMPRENANT UN ENROBAGE D'OXYDE METALLIQUE, ET PARTICULES ENROBEES D'OXYDE METALLIQUE (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING)

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in Canada?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Canada Patent 2,824,842
Patent Title: METHODE DE PREPARATION DE PARTICULES COMPRENANT UN ENROBAGE D'OXYDE METALLIQUE, ET PARTICULES ENROBEES D'OXYDE METALLIQUE (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING)

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can NESINA (alogliptin benzoate) generic drug versions launch in Canada?

Generic name: alogliptin benzoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Canada Patent 2,677,193
Patent Title: PREPARATION DE COMPRIME NE PROVOQUANT PAS DE PROBLEME DE PASTILLAGE (TABLET PREPARATION WITHOUT CAUSING A TABLETING TROUBLE)

Drug Price Trends for NESINA
NESINA is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering NESINA

See drug price trends for NESINA.

The generic ingredient in NESINA is alogliptin benzoate. Additional details are available on the alogliptin benzoate profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Canada?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Canada Patent 2,677,201

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Canada?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Canada Patent 2,677,989

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Canada?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Canada Patent 2,677,989

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Canada?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Canada Patent 2,678,795

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in Canada?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2027
Generic Entry Controlled by: Canada Patent 2,681,465
Patent Title: FORMULATIONS POUR COMPRIMES CONTENANT DES SELS DE 8-[{1-(3,5-BIS- (TRIFLUOROMETHYL)PHENYL)-ETHOXY}-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4,5]- DECAN-2-ONE ET COMPRIMES (TABLET FORMULATIONS CONTAINING 8-[{1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXY}-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM)

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can AMYVID (florbetapir f-18) generic drug versions launch in Canada?

Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: Canada Patent 2,644,530

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.

When can XTANDI (enzalutamide) generic drug versions launch in Canada?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 29, 2027
Generic Entry Controlled by: Canada Patent 2,648,139
Patent Title: COMPOSES DE DIARYLTHIOHYDANTOINE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES D'HYPERPROLIFERATION (DIARYL THIOHYDANTOIN COMPOUNDS AND THEIR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS)

XTANDI is a drug marketed by Astellas. There are seven patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. Additional details are available on the enzalutamide profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in Canada?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 04, 2027
Generic Entry Controlled by: Canada Patent 2,648,604

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can INLYTA (axitinib) generic drug versions launch in Canada?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Canada Patent 2,682,859

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Canada?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Canada Patent 2,648,719
Patent Title: MODULATEURS DES TRANSPORTEURS DE CASSETTES DE LIAISON DE L'ATP (MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Canada?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Canada Patent 2,869,945
Patent Title: MODULATEURS DES TRANSPORTEURS DE CASSETTES DE LIAISON DE L'ATP (MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can TRADJENTA (linagliptin) generic drug versions launch in Canada?

Generic name: linagliptin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2027
Generic Entry Controlled by: Canada Patent 2,649,922

Drug Price Trends for TRADJENTA
TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. Additional details are available on the linagliptin profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Canada?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Canada Patent 2,685,831

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Canada?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: Canada Patent 2,650,273

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Canada?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Canada Patent 2,684,404

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Canada?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Canada Patent 2,683,935

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Canada?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Canada Patent 2,688,478

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Canada?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Canada Patent 2,688,478

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Canada?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Canada Patent 2,690,841
Patent Title: COMPOSITION, PROCEDE ET PREPARATION D'ACIDE BILIAIRE SYNTHETIQUE (SYNTHETIC BILE ACID COMPOSITION, METHOD, AND PREPARATION)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can CARDAMYST (etripamil) generic drug versions launch in Canada?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: Canada Patent 2,693,627
Patent Title: AGENTS BLOQUANT LES CANAUX CALCIQUES A BASE DE PHENYLALKYLAMINE A BREVE DUREE D'ACTION ET LEURS UTILISATIONS (SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF)

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch in Canada?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Canada Patent 2,653,344

Drug Price Trends for BYDUREON
BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. Additional details are available on the exenatide synthetic profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch in Canada?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Canada Patent 2,653,344

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fifteen tentatively approved generics are ready to enter the market. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. Additional details are available on the dapagliflozin profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in Canada?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Canada Patent 2,653,344

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can APLENZIN (bupropion hydrobromide) generic drug versions launch in Canada?

Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 26, 2027
Generic Entry Controlled by: Canada Patent 2,655,596
Patent Title: SYSTEME DE DELIVRANCE OSMOTIQUE MULTIPARTICULAIRE (MULTIPARTICULATE OSMOTIC DELIVERY SYSTEM)

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering APLENZIN

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. Additional details are available on the bupropion hydrobromide profile page.

When can KLISYRI (tirbanibulin) generic drug versions launch in Canada?

Generic name: tirbanibulin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 29, 2027
Generic Entry Controlled by: Canada Patent 2,656,564
Patent Title: COMPOSITIONS DE BIARYLE ET PROCEDES DE MODULATION D'UNE CASCADE DE KINASES (BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE)

KLISYRI is a drug marketed by Almirall. There are seven patents protecting this drug. There has been litigation on patents covering KLISYRI

See drug price trends for KLISYRI.

The generic ingredient in KLISYRI is tirbanibulin. Additional details are available on the tirbanibulin profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in Canada?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Canada Patent 2,657,347
Patent Title: SELS DE BENZODIAZEPINE ET LEURS FORMES POLYMORPHES A ACTION BREVE (SHORT-ACTING BENZODIAZEPINE SALTS AND THEIR POLYMORPHIC FORMS)

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Canada?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Canada Patent 2,692,867
Patent Title: DÉRIVÉS DE PYRIDAZINONE (Pyrimidinyl-pyridazinone derivatives.)

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Canada?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Canada Patent 2,693,600
Patent Title: DERIVES DE PYRIDAZINONE (PYRIDAZINONE DERIVATES)

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in Canada?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Canada Patent 2,694,620

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can TRIFERIC (ferric pyrophosphate citrate) generic drug versions launch in Canada?

Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Canada Patent 2,638,081
Patent Title: PROCEDES DE PREPARATION ET D'UTILISATION DE COMPOSITIONS CHELATEES DE CITRATE DE PYROPHOSPHATE FERRIQUE (METHODS FOR THE PREPARATION AND USE OF FERRIC PYROPHOSPHATE CITRATE CHELATE COMPOSITIONS)

TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.

See drug price trends for TRIFERIC.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. Additional details are available on the ferric pyrophosphate citrate profile page.

When can TRIFERIC AVNU (ferric pyrophosphate citrate) generic drug versions launch in Canada?

Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Canada Patent 2,638,081
Patent Title: PROCEDES DE PREPARATION ET D'UTILISATION DE COMPOSITIONS CHELATEES DE CITRATE DE PYROPHOSPHATE FERRIQUE (METHODS FOR THE PREPARATION AND USE OF FERRIC PYROPHOSPHATE CITRATE CHELATE COMPOSITIONS)

TRIFERIC AVNU is a drug marketed by Rockwell Medical Inc. There is one patent protecting this drug.

See drug price trends for TRIFERIC AVNU.

The generic ingredient in TRIFERIC AVNU is ferric pyrophosphate citrate. Additional details are available on the ferric pyrophosphate citrate profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Canada?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Canada Patent 2,691,445
Patent Title: PROCEDE ENZYMATIQUE POUR OBTENIR DES 17 ALPHA-MONOESTERS DE CORTEXOLONE ET/OU SES DERIVES 9,11-DESHYDRO (ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Canada?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Canada Patent 2,871,025
Patent Title: PROCEDE ENZYMATIQUE POUR OBTENIR DES 17 ALPHA-MONOESTERS DE CORTEXOLONE ET/OU SES DERIVES 9,11-DESHYDRO (ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Canada?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Canada Patent 2,871,039
Patent Title: PROCEDE ENZYMATIQUE POUR OBTENIR DES 17 ALPHA-MONOESTERS DE CORTEXOLONE ET/OU SES DERIVES 9,11-DESHYDRO (ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in Canada?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: Canada Patent 2,660,520
Patent Title: INHIBITEURS DU VIRUS DE L'HEPATITE C (HEPATITIS C VIRUS INHIBITORS)

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can MYRBETRIQ (mirabegron) generic drug versions launch in Canada?

Generic name: mirabegron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 02, 2027
Generic Entry Controlled by: Canada Patent 2,704,298

MYRBETRIQ is a drug marketed by Apgdi. There are six patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering MYRBETRIQ

See drug price trends for MYRBETRIQ.

The generic ingredient in MYRBETRIQ is mirabegron. Additional details are available on the mirabegron profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Canada?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Canada Patent 2,700,444
Patent Title: COMPOSITIONS PHARMACEUTIQUES RENFERMANT UN OXYHYDROXYDE DE FER A FORTE CHARGE (PHARMACEUTICAL COMPOSITIONS COMPRISING IRON OXY-HYDROXIDE IN HIGH LOADING)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Canada?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Canada Patent 2,671,744

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Canada?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2027
Generic Entry Controlled by: Canada Patent 2,668,512

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in Canada?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Canada Patent 2,708,153

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in Canada?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Canada Patent 2,708,171

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in Canada?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Canada Patent 2,708,173

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in Canada?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Canada Patent 2,910,760

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in Canada?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Canada Patent 2,930,393
Patent Title: CONJUGUES GLUCIDIQUES UTILISES EN TANT QU'AGENTS D'ADMINISTRATION POUR DES OLIGONUCLEOTIDES (CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES)

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in Canada?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Canada Patent 3,043,911
Patent Title: LIPIDES DE CIBLAGE (TARGETING LIPIDS)

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in Canada?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Canada Patent 3,146,103
Patent Title: CONJUGUES GLUCIDIQUES UTILISES EN TANT QU'AGENTS D'ADMINISTRATION POUR DES OLIGONUCLEOTIDES (CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES)

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Canada?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: Canada Patent 2,671,614
Patent Title: PRODUITS DERIVES DE 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE SUBSTITUES, UTILES POUR LE TRAITEMENT DE TROUBLES HYPERLIFERATIFS ET DE MALADIES ASSOCIEES A UNE ANGIOGENESE (SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVESUSEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS)

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Canada?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Canada Patent 2,986,286

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Canada?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: Canada Patent 2,672,233

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can ORENITRAM (treprostinil diolamine) generic drug versions launch in Canada?

Generic name: treprostinil diolamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2027
Generic Entry Controlled by: Canada Patent 2,710,205
Patent Title: PROCEDE AMELIORE DE PREPARATION DE TREPROSTINIL, L'INGREDIENT ACTIF DANS LE REMODULIN (AN IMPROVED PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN REMODULIN)

ORENITRAM is a drug marketed by United Therap. There are nine patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering ORENITRAM

See drug price trends for ORENITRAM.

The generic ingredient in ORENITRAM is treprostinil diolamine. Additional details are available on the treprostinil diolamine profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Canada?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Canada Patent 2,655,335

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in Canada?

Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2027
Generic Entry Controlled by: Canada Patent 2,673,486
Patent Title: UTILISATION DE COMPOSES A BASE DE TETRACYCLINE SUBSTITUEE DANS LE TRAITEMENT D'AFFECTIONS CUTANEES INFLAMMATOIRES (SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS)

SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.

See drug price trends for SEYSARA.

The generic ingredient in SEYSARA is sarecycline hydrochloride. Additional details are available on the sarecycline hydrochloride profile page.

When can ONPATTRO (patisiran sodium) generic drug versions launch in Canada?

Generic name: patisiran sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 27, 2027
Generic Entry Controlled by: Canada Patent 2,710,713

ONPATTRO is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering ONPATTRO

See drug price trends for ONPATTRO.

The generic ingredient in ONPATTRO is patisiran sodium. Additional details are available on the patisiran sodium profile page.

When can RYTARY (carbidopa; levodopa) generic drug versions launch in Canada?

Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 28, 2027
Generic Entry Controlled by: Canada Patent 2,711,014
Patent Title: FORMULATIONS À LIBERATION CONTRÔLEE DE LEVODOPA ET LEURS UTILISATIONS (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF)

RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering RYTARY

See drug price trends for RYTARY.

The generic ingredient in RYTARY is carbidopa; levodopa. Additional details are available on the carbidopa; levodopa profile page.

When can SOLUPREP (chlorhexidine gluconate; isopropyl alcohol) generic drug versions launch in Canada?

Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 31, 2027
Generic Entry Controlled by: Canada Patent 2,711,217
Patent Title: COMPOSITIONS ANTIMICROBIENNES (ANTIMICROBIAL COMPOSITIONS)

SOLUPREP is a drug marketed by Solventum.

The generic ingredient in SOLUPREP is chlorhexidine gluconate; isopropyl alcohol. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

Canada Branded and Generic Drug Markets: Regulatory Opportunities, Patent Risks, and Commercial Outlook

Last updated: October 13, 2026

Canada is a regulated, payer-constrained pharmaceutical market with strong demand for lower-cost generics and biosimilars. Branded manufacturers benefit from federal data protection, patent rights, and provincial reimbursement, but face price controls, formulary negotiations, compulsory substitution, and delayed market access. Generic companies have efficient regulatory pathways and substantial volume opportunities, but encounter patent litigation, provincial tendering, supply obligations, and margin compression.

The commercial market is divided across federal, provincial and private-payer systems. Health Canada authorizes products for sale. The Patented Medicine Prices Review Board, or PMPRB, regulates excessive patented-medicine pricing. Provinces determine most public reimbursement through formularies, tenders and purchasing agreements. CADTH and the pan-Canadian Pharmaceutical Alliance, or pCPA, influence national reimbursement and price negotiations.

How large is the Canadian branded and generic drug market?

Canada is one of the largest pharmaceutical markets in the Americas, but it is materially smaller than the United States and operates under more centralized reimbursement controls.

Market segment Main commercial characteristics Principal decision-makers
Branded small molecules Patent and regulatory exclusivity; negotiated reimbursement; PMPRB oversight Health Canada, PMPRB, CADTH, pCPA, provinces
Generic small molecules Abbreviated approval pathway; substitution and tendering; low prices Health Canada, provincial formularies, private insurers
Biologics High development costs; provincial reimbursement; biosimilar competition Health Canada, CADTH, pCPA, provinces
Biosimilars Increasing substitution and interchangeability policies Health Canada, provincial ministries, hospitals
Hospital products Group purchasing, tenders and supply reliability Provincial hospitals, group purchasing organizations
Specialty drugs High per-patient cost; restricted access and managed entry CADTH, pCPA, private payers, provinces

Generic and biosimilar products account for a large share of prescription volume, while patented and specialty products account for a disproportionate share of spending. PMPRB reported that patented medicines represented about 75% of Canadian pharmaceutical sales in 2022, based on its patented-medicine market measures, although this does not represent the entire retail or hospital market.[1]

Canada has a mixed private and public reimbursement structure. Provincial public plans cover approximately two-thirds of prescription drug spending, while private insurance, employer plans and patient payments cover the remainder.[2] The division varies by province, age group, disease and drug category.

What are the main regulatory pathways for branded and generic drugs in Canada?

Health Canada regulates prescription drugs under the Food and Drugs Act and Food and Drug Regulations. The regulatory pathway depends on whether the product is innovative, generic, biologic, biosimilar or an authorized copy of an existing product.

Branded drugs

Innovative drugs generally require a New Drug Submission, or NDS. The filing must establish quality, safety and efficacy. Health Canada may grant:

  • A standard Notice of Compliance, or NOC.
  • A priority review for products addressing serious or life-threatening conditions.
  • A Notice of Compliance with conditions, or NOC/c, for products with promising evidence and a favorable benefit-risk profile but outstanding confirmatory obligations.
  • A special access or exceptional access authorization in limited circumstances.

The standard review target for a priority NDS is six months, compared with approximately ten months for a standard NDS, subject to filing quality and review requirements.[3]

Generic drugs

Generics generally use an Abbreviated New Drug Submission, or ANDS. The sponsor must demonstrate pharmaceutical equivalence and bioequivalence to a Canadian reference product, rather than repeat the originator’s full clinical program.

The generic must comply with Health Canada’s product-specific requirements, manufacturing standards, labeling rules and patent-related requirements. The pathway is faster and less expensive than an NDS, but approval does not necessarily permit immediate commercialization if patent litigation or data-protection restrictions remain active.

Biosimilars

Biosimilars are reviewed through a New Drug Submission rather than the generic ANDS pathway. The sponsor must establish similarity to the reference biologic through analytical, nonclinical and clinical evidence.

Health Canada can designate a biosimilar as interchangeable, but interchangeability is generally determined by provinces and territories. Provincial substitution policies therefore have a direct effect on commercial uptake. A biosimilar may receive federal approval without obtaining automatic substitution across Canada.

What patents protect drugs in Canada?

Canadian drug patent protection is based principally on the Patent Act and the Patented Medicines Regulations. A standard patent term is 20 years from the Canadian filing date for applications filed under the modern patent system.[4]

Canada does not use the U.S. Orange Book. The relevant federal system is the Health Canada Patent Register, which lists patents submitted by innovative-drug sponsors for linkage to later generic or biosimilar applications.

Canadian right or protection Typical duration or effect
Standard patent term 20 years from filing
Patent Register listing Links listed patents to later generic or biosimilar applications
Innovative-drug data protection Generally eight years
Pediatric extension Six additional months in qualifying cases
Certificate of Supplementary Protection Up to two years for eligible innovative drugs
Regulatory review Health Canada approval requirement before sale

The Patent Register is narrower than a complete patent landscape. A sponsor cannot necessarily list every patent covering a product, and a patent may be commercially relevant without being listed for linkage purposes.

What formulations are protected by Canadian patents?

Formulation patents may cover:

  • Extended-release tablets and capsules.
  • Injectable compositions.
  • Stabilizers, buffers and excipients.
  • Device-based delivery systems.
  • Long-acting or depot formulations.
  • Specific particle sizes or solid-state forms.
  • Combination products.
  • Manufacturing processes.
  • Dosage regimens and administration schedules.

Formulation and device patents can extend commercial protection beyond the expiry of the basic compound patent. Their strength depends on claim scope, enablement, validity, infringement evidence and whether the patent is listed in the Patent Register.

What method-of-use patents protect a drug?

Method-of-use patents cover treatment of a defined disease, patient population, biomarker group or dosing schedule. They can create launch barriers for generic products even when the compound patent has expired.

A generic sponsor may seek approval for non-patented uses while excluding protected indications from its product monograph. That approach can reduce litigation exposure but creates labeling, distribution and prescriber-communication risks. Courts assess the actual conduct of the generic sponsor, including labeling, promotion and foreseeable use.

When do branded drugs lose exclusivity in Canada?

There is no single Canadian exclusivity date. Commercial exposure depends on the interaction of patents, data protection, supplementary protection, pediatric extensions, regulatory approval and provincial listing.

A typical sequence is:

Event Commercial consequence
NDS approval Product may be sold, subject to market authorization
Eight-year data-protection period Certain subsequent-entry submissions cannot rely on the innovator’s data
Six-month pediatric extension Extends qualifying data protection
Patent expiry Removes the relevant patent barrier, subject to other patents
Generic NOC Regulatory approval for the generic
Patent litigation resolution May determine whether the generic can receive or use its NOC
Provincial listing Determines public reimbursement and effective market access

The Canadian data-protection regime generally prevents a subsequent-entry manufacturer from filing an application relying on the innovator’s undisclosed data for eight years after the innovative drug is first approved. The regime does not create a patent, and it does not automatically prevent an independent application supported by the sponsor’s own data.[5]

Certificates of Supplementary Protection can add up to two years to protection for eligible innovative drugs, subject to statutory conditions and maximum limits.[6]

How do Paragraph IV challenges work in Canada?

Canada does not use the U.S. Paragraph IV label, although the strategic function is similar. A generic or biosimilar sponsor typically delivers a Notice of Allegation to the innovator when asserting that listed patents are invalid, not infringed or irrelevant to the proposed product.

The innovator may bring an application under the Patented Medicines Regulations, commonly known as the PM(NOC) proceedings. The proceeding concerns whether Health Canada should issue an NOC before the patent dispute is resolved.

Under the modern framework:

  1. The generic or biosimilar files its submission.
  2. It serves a Notice of Allegation against relevant listed patents.
  3. The innovator can bring a Federal Court application within the statutory period.
  4. The court assesses the patent allegations and the proposed product.
  5. A statutory prohibition period may delay issuance of the NOC, subject to court orders and statutory limits.

A court proceeding does not necessarily result in a full damages trial. The innovator may later pursue an infringement action after launch, while the generic can face damages or an injunction if the product infringes a valid patent.

What is the Canadian equivalent of the Orange Book?

Canada has no Orange Book. Market participants should use three federal sources:

  • Health Canada’s Drug Product Database for approved products and regulatory status.
  • Health Canada’s Patent Register for patents associated with eligible drugs.
  • Health Canada’s Regulatory Decision Summaries for selected approval information.

The Patent Register is central to generic launch analysis, but it should be supplemented with a complete Canadian patent search covering formulation, process, device and method-of-use claims.

What regulatory opportunities exist for branded manufacturers?

Specialty and orphan drugs

Canada offers commercial opportunities for rare-disease therapies, oncology drugs and specialty biologics. High unmet need can support priority review, NOC/c authorization, provincial risk-sharing arrangements and targeted reimbursement.

The challenge is that regulatory approval does not guarantee reimbursement. CADTH’s health-technology assessment and pCPA negotiations can delay broad public access, particularly for products with high budget impact.

Supplementary Protection Certificates

Eligible innovative products can receive additional patent protection through the Canadian Certificate of Supplementary Protection regime. Sponsors must monitor filing deadlines and coordinate Canadian and foreign regulatory strategy because eligibility depends on regulatory approval and patent conditions.

Real-world evidence and managed access

Provincial plans and pCPA increasingly use outcomes-based agreements, confidential rebates and restricted listings. These mechanisms can support launch of high-cost products while limiting payer exposure.

Local manufacturing and supply reliability

Canada’s public buyers place value on supply continuity. Branded companies with Canadian packaging, dual sourcing or reliable cold-chain infrastructure can improve tender and hospital positioning, particularly for injectable and shortage-prone products.

What regulatory opportunities exist for generic and biosimilar manufacturers?

Generic companies benefit from:

  • The ANDS pathway.
  • Patent expiry and invalidity challenges.
  • Provincial substitution policies.
  • Public tendering.
  • Hospital purchasing contracts.
  • Private-plan substitution.
  • Portfolio licensing and co-marketing.

Biosimilar companies have a growing opportunity as provinces expand biosimilar switching policies. British Columbia, Alberta, Manitoba, Quebec and other provinces have implemented or expanded policies requiring or encouraging patients to transition from reference biologics to biosimilars in selected indications.[7]

A biosimilar’s commercial success depends on more than approval. It requires provincial interchangeability treatment, physician and patient adoption, reimbursement listing, supply reliability and competitive net pricing.

What challenges face branded drug companies in Canada?

The principal risks are:

  1. PMPRB price review and possible price reductions.
  2. Delayed CADTH and pCPA reimbursement.
  3. Provincial formulary restrictions.
  4. Confidential rebates that reduce net price.
  5. Generic or biosimilar substitution.
  6. Method-of-use and formulation litigation.
  7. Parallel trade and cross-border pricing pressure.
  8. Mandatory supply and shortage-management obligations.
  9. Different provincial rules for public reimbursement.
  10. Limited commercial scale relative to development costs.

The 2022 PMPRB Guidelines introduced a revised framework for patented-medicine price review, but implementation has been affected by litigation, consultation and regulatory change. Sponsors must track both the formal regulations and current PMPRB enforcement practice.[1]

What challenges face generic and biosimilar companies?

Generic manufacturers face intense price competition, particularly after multiple entrants. Provincial tendering can produce rapid price erosion and concentration of market share among a small number of suppliers.

Supply interruptions are a material risk. A low-price contract may become uneconomic when manufacturing costs, active pharmaceutical ingredient costs, freight or quality-compliance costs rise. Health Canada shortage reporting and provincial supply obligations can increase operational exposure.

Biosimilar manufacturers face higher development costs than conventional generics. They also compete against reference biologics that may reduce net prices through rebates and contracting. A biosimilar with a lower list price may not achieve rapid uptake if the reference product has strong formulary positioning.

Which companies compete in Canada’s branded and generic markets?

Major branded participants include multinational pharmaceutical companies such as Roche, AbbVie, Merck, Pfizer, AstraZeneca, Sanofi, Novartis, Bristol Myers Squibb and Johnson & Johnson.

Major generic and biosimilar participants include:

  • Apotex.
  • Sandoz.
  • Teva Canada.
  • Pharmascience.
  • Viatris.
  • Sun Pharma.
  • Fresenius Kabi.
  • Biocon Biologics.
  • Celltrion.
  • Organon.
  • Amgen and other biologic manufacturers with biosimilar portfolios.

Market share varies by product, province, tender result and reimbursement channel. A national ranking can be misleading because hospital, retail, specialty pharmacy and private-plan markets operate differently.

What licensing deals and commercial structures are common?

Canadian licensing arrangements commonly use:

  • Territory-specific commercialization licenses.
  • Co-promotion agreements.
  • Supply and distribution agreements.
  • Authorized-generic arrangements.
  • Biosimilar commercialization partnerships.
  • Technology-transfer and contract-manufacturing agreements.
  • Settlement-linked licenses after patent litigation.

The licensee may assume Health Canada filing, pharmacovigilance, product liability and provincial reimbursement responsibilities. The agreement should allocate Patent Register strategy, PM(NOC) litigation costs, shortage obligations, recalls and Canadian-specific labeling.

Settlement agreements involving delayed generic entry can raise competition-law and regulatory scrutiny. Parties must analyze the Competition Act, patent litigation rules and any payment or supply provisions before execution.

What patent litigation affects Canadian market entry?

Canadian generic litigation generally focuses on:

  • Patent validity.
  • Claim construction.
  • Infringement by the proposed product.
  • Relevance of listed patents.
  • Dosage-form and formulation differences.
  • Labeling and induced infringement.
  • The timing of the generic’s NOC.
  • Damages from delayed or premature launch.

The Federal Court and Federal Court of Appeal are the primary venues for PM(NOC) disputes. Litigation risk is highest where an innovator has layered compound, formulation, method-of-use and device patents.

A generic launch before resolution can generate substantial damages exposure. A delayed launch can sacrifice first-mover economics, especially where provincial procurement awards favor the first approved or first listed supplier.

How does Canada compare with the United States?

Issue Canada United States
Product listing system Health Canada databases and Patent Register FDA Orange Book and Purple Book
Patent linkage PM(NOC) framework Hatch-Waxman and biologic litigation frameworks
Standard patent term 20 years from filing 20 years from filing
Drug pricing PMPRB and payer negotiations More decentralized, with federal and private components
Generic approval ANDS ANDA
Biosimilar approval NDS-based pathway 351(k) pathway
Public reimbursement Primarily provincial Federal, state and private systems
Market scale Smaller Much larger
Price erosion after entry Often rapid Variable, often driven by entrant count

Canada generally offers lower launch economics but a clearer national regulatory structure for subsequent-entry products. The United States offers greater revenue potential and a more formalized patent-listing and litigation architecture.

What generic launch scenarios exist in Canada?

First entrant after compound-patent expiry

This scenario offers the strongest price and volume opportunity but attracts the highest litigation intensity. Provincial listing and supply capacity are critical.

Launch after formulation-patent expiry

The generic may need a differentiated dosage form, a non-infringing formulation or a targeted product monograph. Manufacturing complexity can reduce the number of competitors.

Non-infringing carve-out launch

The sponsor excludes protected indications or dosing information. This can support earlier launch but may reduce the addressable market and create induced-infringement risk.

Multi-source tender launch

Several approved suppliers compete for provincial or hospital contracts. The winning supplier can obtain volume, but price compression is usually severe.

Biosimilar interchangeability launch

The product receives federal approval and provincial substitution support. Uptake depends on switching rules, physician acceptance and payer contracting.

What is the overall strength of Canada’s pharmaceutical patent estate?

Canada has a meaningful but narrower commercial patent estate than the United States. Compound patents provide the strongest protection. Formulation, device, process and method-of-use patents can preserve value but are more vulnerable to validity and infringement challenges.

Patent strength should be assessed product by product using:

  • Remaining patent term.
  • Patent Register status.
  • Claim breadth.
  • Validity risk.
  • Generic formulation differences.
  • Method-of-use carve-out feasibility.
  • Provincial reimbursement concentration.
  • Biosimilar or generic development status.
  • Settlement and licensing history.
  • Manufacturing complexity.

Key Takeaways

  • Canada has a large, sophisticated pharmaceutical market with lower prices and more centralized payer control than the United States.
  • Health Canada approval is separate from reimbursement, provincial listing and commercial access.
  • Canada has no Orange Book. The Health Canada Patent Register is the principal patent-linkage resource.
  • Generic sponsors use Notices of Allegation and PM(NOC) litigation rather than the U.S. Paragraph IV process.
  • Branded products may receive eight years of data protection, a six-month pediatric extension and up to two years of supplementary patent protection where eligible.
  • Generic opportunities are strongest after compound-patent expiry and in products with limited competition or manufacturing complexity.
  • Biosimilar growth depends on provincial substitution and switching policies.
  • PMPRB pricing review, CADTH assessment, pCPA negotiation and provincial formularies are the main branded-market constraints.
  • Patent, regulatory, reimbursement and supply-chain analysis must be performed together before a Canadian launch decision.

Frequently Asked Questions

Does Canada allow generic entry before patent expiry?

Yes. A generic sponsor can challenge listed patents through a Notice of Allegation and PM(NOC) proceedings. Commercial launch depends on the outcome of the litigation, the patent claims and any remaining data-protection restrictions.

Are Canadian drug patents listed in the U.S. Orange Book?

No. Canada does not use the U.S. Orange Book. Canadian drug patents are listed, where eligible, in the Health Canada Patent Register.

Do Canadian biosimilars automatically substitute for reference biologics?

No. Health Canada approves the biosimilar, but provinces generally determine interchangeability and substitution policy.

Can a Canadian generic launch with a restricted label?

Yes. A sponsor may attempt to omit protected indications or dosing information. The strategy must avoid infringement and induced-infringement exposure.

Which Canadian provinces are most important for generic market access?

Ontario, Quebec, British Columbia and Alberta are generally the most commercially significant provincial markets because of population, prescription volume, public-plan enrollment and hospital purchasing influence. Their reimbursement and substitution rules differ.

References

  1. Patented Medicine Prices Review Board. (2024). Annual report 2023-2024. Government of Canada.

  2. Canadian Institute for Health Information. (2024). National health expenditure trends, 2024: Canadian health spending, 1975 to 2024. CIHI.

  3. Health Canada. (2024). Guidance document: The management of drug submissions and applications. Government of Canada.

  4. Government of Canada. (2024). Patent Act, RSC 1985, c. P-4. Justice Laws Website.

  5. Health Canada. (2024). Data protection for innovative drugs. Government of Canada.

  6. Government of Canada. (2024). Certificate of Supplementary Protection Regulations, SOR/2017-166. Justice Laws Website.

  7. Canadian Agency for Drugs and Technologies in Health. (2024). Biosimilars in Canada: Current status and provincial policy developments. CADTH.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.